Drug Profile


Alternative Names: Octreotide acetate; Octreotide hydrochloride; Octreotide pamoate; Oncolar; Sandostatin LAR Depot; SMS 201995 ac; SMS 201995 pa; SMS 201995 pa LAR; SMS pa; SMS-201-995; SMS-995; SMS-995-AAA

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Intestinal obstruction; Malignant carcinoid syndrome; Neuroendocrine tumours
  • Phase II Diarrhoea
  • Discontinued Diabetic retinopathy; Polycystic liver disease; Prostate cancer; Thymoma

Most Recent Events

  • 03 Mar 2015 Discontinued - Phase-II/III for Polycystic liver disease, Prostate cancer and Thymoma in USA (IM)
  • 03 Mar 2015 No recent reports on development identified - Phase-III for Neuroendocrine tumours in Germany (IM)
  • 03 Mar 2015 No recent reports on development identified - Phase-III for Diarrhoea (Prevention, Chemotherapy-induced) in Brazil (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top